Risk factor
Poor trading liquidity
Profitability factor
Very favourable analyst view
About
Ever Fortune.AI Co., Ltd. specializes in delivering cloud-based artificial intelligence solutions. Their product portfolio features a bone age evaluation system, which assists clinicians in determining a child's skeletal age and predicting their ultimate adult height. They also offer a sophisticated breast ultrasound tumor categorization system, designed to empower medical practitioners in tumor diagnosis and facilitate non-invasive screening to guide breast puncture and biopsy decisions concerning tumor malignancy. Additionally, the company provides a computed tomography-based system for assessing liver cancer metastatic risk, thereby enhancing radiologists' operational efficiency and evaluating the potential for metastasis. Their suite of tools further includes a liver fibrosis assessment system designed to measure liver scarring, and an atrial fibrillation detection system that interprets electrocardiogram signals to evaluate the heart's condition. Headquartered in Taichung City, Taiwan, Ever Fortune.AI Co., Ltd. operates as a subsidiary of An Ji Biomedical Corporation.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, 'expensive' on EV/EBITD.